£3.36m European Regional Development Fund (ERDF) award will support the construction of a further six modules at the CGT Catapult manufacturing centre, doubling existing capacity.
The £3.36m ERDF award will contribute to significantly increasing the current size and capability of the Cell and Gene Therapy Catapult (CGT Catapult) large-scale GMP manufacturing centre. The award, which builds on over £60 million government investment in the project, will allow the centre’s capacity to double. This will offer businesses developing cell therapy products further opportunities to accelerate manufacturing for their trials and worldwide commercialisation of their therapies.
The Stevenage-based manufacturing centre, officially opened in April 2018, allows companies to develop their large scale GMP and commercial manufacture in collaboration and benefitting from the end-to-end expertise and practical support from CGT Catapult experts across scientific research, manufacturing, supply and regulation.
The centre features a series of large clean room modules which can be occupied by businesses conducting trials or commercial manufacture of these therapies at significant scale.